Skip to main content

Table 1 Patient characteristics

From: High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study

 

Patients

Controls

Normal values

Gender (M/F)

15/14

10/9

 

Age (years)

35 (24–50)

44 (38–57)

 

BMI

23.0 (20.6–24.1)

  

Amylase (U/L)

43 (25–59)

 

10–65

Lactatdehydrogenase (U/L)

161 (136–180)

 

105–205

ALT (U/L)

39 (24–75)

 

10–70

Bilirubin (umol/L)

9 (8–14)

 

5–25

Alkaline phosphatase (U/L)

96 (74–125)

 

35–105

PP factor 2, 7, 10

0.82 (0.69-0.90)

 

0.6-1.30

Potassium (mmol/L)

4.0 (3.8–4.1)

 

3.5–4.6

Sodium (mmol/L)

140 (139–142)

 

137–145

Albumine (g/L)

38 (36–41)

 

36–48

Creatinine (umol/L)

69.0 (60.0–87.0)

 

45–105

eGFR (mL/min 1.73m2)

91 (89–91)

 

> 60

B-leukocytes (10^9/l)

6.1 (5.1–6.5)

 

3.5–10.0

Haemoglobin (mmol/L)

8.9 (8.2–9.2)

 

7.3–10.5

Platelets (10^9/L)

204 (151–242)

 

165–400

Iron (umol/L)

15 (12–21)

 

9–34

Transferrin (umol/L)

34 (31–37)

 

24–41

Transferrin-saturation

0.3 (0.2–0.3)

 

0.10–0.57

Haptoglobin (g/L)

0.9 (0.6–1.3)

 

0.35–1.85

Zinc in blood (umol/L)

17 (12–25)

 

10–19

Zinc in 24-h urine (umol/24 h)

37.10 (16.00–68.25)

 

6–12

Copper in 24-h urine (umol/24 h)

5.3 (1.7–8.1)

 

0–1.5

MELD-score

8 (7–9)

  
  1. Parameters are presented as medians (interquartile range). BMI, body mass index; ALT, alanine transferase; MELD, Model of End-stage Liver Disease